You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复宏汉霖-B(02696.HK):HLX14用于高危骨折风险的女性绝经后骨质疏松症的1期临床研究完成首例患者给药
格隆汇 11-09 17:11

格隆汇 11 月 9日丨复宏汉霖-B(02696.HK)发布公告,今日,公司研制的重组抗RANKL全人单克隆抗体注射液HLX14用于高危骨折风险的女性绝经后骨质疏松症的1期临床研究于中国大陆境内完成首例患者给药。

根据披露,该研究是一项在男性健康受试者中开展的HLX14的两阶段1期临床试验。第一阶段为比较HLX14和欧洲市售的地舒单抗在皮下给药后的药物代谢动力学特征、药效学、安全性、耐受性和免疫原性的开放、随机、平行对照、单次给药、双臂的预试验研究。第二阶段是一项双盲、随机、平行对照、单次给药、4臂的研究,其主要目的是比较HLX14与美国、欧洲及中国大陆市售的地舒单抗的药物代谢动力学特征的相似性,次要目的是评估HLX14与对照药的药效学、安全性、耐受性和免疫原性的相似性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account